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Prevalence and determinants of hyperhomocysteinemia in he- are unclear and may include relative or absolute defi-
modialysis and peritoneal dialysis. ciencies of folic acid, vitamin B12, or vitamin B6 [5–10].Background. Hyperhomocysteinemia is an independent risk Reduced renal metabolism of homocysteine has also beenfactor for atherosclerotic complications in patients with end-
proposed [11]. Additionally, there may be differencesstage renal disease, although the mechanisms remain unclear.
The major determinants of plasma homocysteine concentration in homocysteine levels and folate metabolism between
are usually folate, vitamin B12, pyridoxal 59-phosphate (vitamin patients on peritoneal dialysis (PD) versus hemodialysis
B6), and glomerular filtration rate. (HD) [4, 5]. This study extends our previous descriptionMethods. We measured factors, including plasma folate, vi-
of hyperhomocysteinemia in patients with ESRD on di-tamin B12, vitamin B6, creatinine, as well as the dose and dura-
tion of dialysis, that might affect plasma homocysteine concen- alysis [6] and compares the prevalence and determinants
trations in 130 patients on hemodialysis (HD) and compared of hyperhomocysteinemia in patients treated with PD ver-
these observations with those in 46 patients on peritoneal dial- sus HD. The results show that the duration and modeysis (PD). Independent determinants of total homocysteine
of dialysis are important determinants of plasma homo-were identified using a multiple logistical regression analysis.
cysteine in patients with ESRD and that the effects ofResults. Total homocysteine values averaged 29.8 mmol/liter
in HD patients, significantly higher than the mean value of folate on homocysteine levels may be saturated in pa-
19.9 mmol/liter observed in patients on PD (P , 0.001). The tients on PD.
prevalence of hyperhomocysteinemia was 90.8% among HD
patients, significantly higher than the prevalence of 67.4%
among PD patients. Folate values in HD patients averaged
METHODS45.5 nmol/liter and were significantly lower than in PD patients
(104.2 nmol/liter, P , 0.001). For patients on HD, the only Patients
determinant of total homocysteine concentration was plasma
We acquired data from 176 random patients withfolate (r 5 20.31, P , 0.001). In contrast, for PD patients, total
homocysteine did not correlate with plasma folate, vitamin B12, ESRD that were treated in our facilities with HD (N 5
or vitamin B6. 130) or PD (N 5 46). Demographic details have been
Conclusions. Hyperhomocysteinemia is more prevalent and reported previously [5]. All patients received standardintense in HD patients compared with those on PD. The homo-
care on ambulatory PD or cycled PD or HD three timescysteine response may become refractory to excess folate sup-
per week using high-flux polysulfone membranes (F80B,plementation in PD patients.
Fresenius). For patients on HD, the dialysis dose (Kt/V)
by single pool kinetics averaged 1.24 6 0.22 (6 sd),
Hyperhomocysteinemia is a common finding in patients with a range between 0.70 and 1.80. For patients on PD,
with end-stage renal disease (ESRD) [1–10] and is a risk creatinine clearance (CCr; measured as a combination of
factor for atherosclerotic complications in these patients urine and dialysate clearances) averaged 57.7 6 21.3 liter/
[1–8]. The mechanisms of hyperhomocysteinemia in ESRD week, with a range between 32.4 and 131.5. All patients
were counseled to consume a protein intake of 1 g/kg
body wt/day and daily multivitamins. Compliance withKey words: renal failure, vascular disease, homocyteine, folic acid,
dialysis. vitamin supplementation (Nephrocaps, one tablet daily,
which includes 1 mg folic acid, 6 mg cyanocobalamin,
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Methods independent predictors of tHcy, a multiple regression
model was constructed that included age, sex, race, dia-Total fasting plasma homocysteine (tHcy) was mea-
betes, hypertension, smoking, total cholesterol, folate,sured using the technique of Jacobsen et al on samples
vitamin B12, vitamin B6, creatinine, Kt/V (for HD pa-drawn prior to HD or at regular visits for patients on
tients), CCr (for PD patients), duration, and mode ofPD [12]. All forms of plasma homocysteine are deter-
dialysis as the independent variables, and tHcy as themined in this assay, including reduced (homocysteine)
outcome variable.and oxidized (homocystine, homocysteine–cysteine mixed
disulfide, and protein-bound homocysteine mixed disul-
fide) forms. These forms are collectively referred to as RESULTS
total homocysteine. Hyperhomocysteinemia is defined as Plasma homocysteine
a concentration greater than the 95th percentile for our
As reported previously [5], the mean tHcy was highercontrol population (16.5 mmol/liter) [5]. Plasma vitamin
in ESRD patients than in the normal population (26.8levels were measured using blood samples drawn at the
mmol/liter, 95% CI, 24.7 to 29.0 vs. 10.5 mmol/liter, 95%time of measurement of homocysteine. A commercial
CI, 10.1 to 10.9, P , 0.001), and hyperhomocysteinemiaradioligand-binding assay (Simultrac; Becton Dickinson,
occurred in 149 (85%) ESRD patients. Total plasmaOrangeburg, NY, USA) was used for the measurement
homocysteine values were significantly higher in patientsof the concentrations of folic acid, vitamin B12, and vita-
on HD than in patients on PD (29.8 mmol/liter, 95% CI,min B6 [13]. Deficiencies of folic acid, vitamin B12, or 27.0 to 32.8 vs. 19.9 mmol/liter, 95% CI, 17.8 to 22.2, P ,vitamin B6 were defined as concentrations of less than 6.4 0.001; Table 1). The prevalence of hyperhomocysteine-nmol/liter, 125 pmol/liter, and 20 nmol/liter, respectively.
mia was also higher among HD patients at 90.8% as
compared with 67.4% among PD patients (P 5 0.001).Associated risk factors for vascular disease
Total fasting cholesterol, high-density lipoprotein cho- Determinants of plasma homocysteine in all end-stage
lesterol, low-density lipoprotein cholesterol, and glucose renal disease patients
were measured using standard laboratory techniques.
As shown in Table 1, plasma folate levels were higher
Smoking was considered as a dichotomous variable, and
in PD patients than in HD patients (104.2 nmol/liter,
subjects were classified either as current smokers (if they 95% CI, 78.3 to 138.8 vs. 45.5 nmol/liter, 95% CI, 38.1
were still smoking) or not (if they had never smoked or to 54.2, P , 0.001). Vitamins B12 and B6 were higher inwere quitting smoking). Hypertension was defined as PD patients than in HD patients (vitamin B12 values:an average blood pressure greater than 140/90 mm Hg 646.2 pmol/liter, 95% CI, 577.6 to 723.0 vs. 385.4 pmol/
measured at predialysis for HD and at monthly visits for liter, 95% CI, 357.1 to 416.0, P , 0.001; vitamin B6 values:PD patients, or dependence on antihypertensive medica- 101.2 nmol/liter, 95% CI, 80.3 to 127.5 vs. 56.3 nmol/
tions with a history of hypertension. Diabetes mellitus liter, 95% CI, 47.3 to 66.9, P , 0.001). In univariate
was diagnosed if patients were using insulin or oral hypo- analysis in all ESRD patients (Table 2), tHcy correlated
glycemic agents or if the fasting glucose concentration negatively with plasma folate, vitamins B12 and B6, and
was greater than 140 mg/dl. current smoker status and correlated positively with cre-
atinine, duration of dialysis, and HD rather than PD. InStatistics
multivariate analysis, independent determinants of tHcy
Descriptive statistics are reported as frequency and included plasma folate, vitamin B12, and creatinine (Ta-
percentage for categorical data and as mean and stan- ble 3). The mean duration of dialysis in all ESRD patients
dard deviation for continuous data. The data for tHcy, was 31.6 months (95% CI, 26.7 to 37.3; Table 1). This
total cholesterol, folate, vitamin B12, vitamin B6, creati- was higher in patients on HD than in those on PD (34.8
nine, Kt/V (for HD patients), and CCr (for PD patinets) months, 95% CI, 28.3 to 42.8 vs. 24.0 months, 95% CI,
were transformed to natural logarithms for analysis. The 18.6 to 31.1, P 5 0.03; Table 1). Because dialysis mode
logarithmic transformation reduced the pronounced pos- was a determinant of hyperhomocysteinemia, we ana-
itive skew and decreased the variation, making the data lyzed the data from HD and PD patients separately.
more nearly normally distributed. The geometric mean
Hemodialysis patientsand 95% confidence interval are reported for these vari-
ables. Percentages were compared using Pearson’s chi- In univariate analysis, determinants of plasma homo-
squared test or Fisher’s exact test, depending on the cysteine in HD patients included plasma folate, vitamin
frequencies. Continuous variables were compared using B12, vitamin B6, creatinine, duration of dialysis, and cur-
Student’s t-test. The Pearson correlation was used to rent smoker status (Table 2). In these patients, there was
determine the strength of association between tHcy and a significant negative correlation between homocysteine
and folate (r 5 20.51, P , 0.001; Fig. 1), and there wereother predictor variables. To determine the significant
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Table 1. Total homocysteine (tHcy), folate, vitamin B12 and duration of dialysis (geometric means and 95% confidence intervals)
in controls, ESRD, HD and PD patients
Controls ESRD HD PD
tHcy lmol /liter 10.5 (10.1–10.9) 26.8a (24.7–29.0) 29.8 (27.0–32.8) 19.9b (17.8–22.2)
Folate nmol /liter 15.6 (14.5–16.7) 56.5a (48.3–66.2) 45.5 (38.1–54.2) 104.2b (78.3–138.8)
Vitamin B12 pmol /liter 256.6 (243.4–270.6) 441.5a (411.0–474.3) 385.4 (357.1–416.0) 646.2b (577.6–723.0)
Vitamin B6 nmol /liter 64.9 (59.3–71.0) 65.7 (56.8–76.0) 56.3 (47.3–66.9) 101.2b (80.3–127.5)
Duration of dialysis months NA 31.6 (26.7–37.3) 34.8 (28.3–42.8) 24.0b (18.6–31.1)
NA is not applicable.
a P , 0.05 vs. controls
b P , 0.05 vs. HD
Table 3. Independent determinants of tHcy in ESRD, PD and HDTable 2. Variables significantly correlated with tHcy by univariate
analysis in ESRD, PD and HD patients patients in multivariate analysis (b estimate 6 se)
ESRD PD HDr P
Ln folate Ln folate 20.2060.04a NS 20.3160.05a
Ln vitamin B12 20.1860.09b NS NSESRD patients 20.50 ,0.001
PD patients 20.16 NS Ln vitamin B6 NS NS NS
Ln creatinine 0.20 60.09 0.3860.14b NSHD patients 20.51 ,0.001
Ln vitamin B12 LnKt/V NA NA NS
Ln CCl NA NS NAESRD patients 20.40 ,0.001
PD patients 20.18 NS Ln duration of dialysis NS NS NS
Current smoker NS NS NSHD patients 20.32 ,0.001
Ln vitamin B6 Abbreviations are: NS, not significant; NA, not applicable; Ln, log transformed
ESRD patients 20.31 ,0.001 numbers.
PD patients 0.14 NS a P , 0.001
HD patients 20.32 ,0.001 b P , 0.05
Ln creatinine
ESRD patients 0.26 ,0.001
PD patients 0.45 ,0.01
HD patients 0.02 ,0.01
Ln duration of dialysis cluster in the higher range. In univariate analysis, creati-
ESRD patients 0.20 ,0.01 nine emerged as the major measured determinant of
PD patients 0.19 NS
plasma homocysteine in PD patients (r 5 0.45, P , 0.01;HD patients 0.15 ,0.05
Current smoker status Table 2), and correlations between homocysteine and
ESRD patients 20.14 0.05 folate (r 5 20.16; Fig. 1), vitamin B12 (r 5 20.18) orPD patients 20.10 NS
vitamin B6 (r 5 0.14), or CCr (r 5 20.11; Table 2) were notHD patients 20.18 ,0.05
Ln Kt/V significant. In multivariate analysis, the only independent
HD patients 0.04 NS determinant of plasma homocysteine in PD patients was
Ln CCl creatinine (Table 3).PD patients 20.11 NS
Because residual renal function in patients on PDAbbreviations are: Ln, natural logarithm; NS, not significant.
could explain some of these differences, we separately
analyzed those with residual function assessed by clini-
cally significant urine output. Fifteen of the 46 patients on
weaker, but significant, negative correlations between PD had residual renal function, with weekly creatinine
homocysteine and vitamin B12 (r 5 20.32, P , 0.001), clearances that averaged 83.6 6 23.2 liter/week, signifi-
vitamin B6 (r 5 20.32, P , 0.001), and current smoker cantly higher than the mean value of 47.8 6 8.6 liter/
status (r 5 20.18, P , 0.05). A positive correlation week observed in the 31 PD patients without residual
existed between plasma homocysteine and creatinine (r 5 function (P , 0.001). There was no difference, however,
0.02, P , 0.01). Kt/V did not correlate with homocys- in the mean values for tHcy (22.1 6 8.6 vs. 20.8 6 8.3
teine. In multivariate analysis, independent determinants mmol/liter).
of plasma homocysteine included only folate (Table 3).
DISCUSSIONPeritoneal dialysis
These studies show important differences in the preva-As shown in Figure 1, there were notable differences
lence and determinants of plasma homocysteine concen-between PD and HD patients in their plasma homocys-
trations in patients receiving HD versus those receivingteine and folate levels and the relationship between the
PD. Hyperhomocysteinemia was more prevalent andtwo. For patients on PD, homocysteine levels cluster
below those of patients on HD, and plasma folate values more intense in HD patients and was associated with
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Fig. 1. Correlation between plasma homo-
cysteine and folate in hemodialysis and perito-
neal dialysis patients. Symbols are: (s) hemo-
dialysis; (d) CAPD; the solid line indicates
the mean negative correlation in hemodialysis
patients, and the dashed line indicates the
mean correlation in CAPD patients.
lower plasma concentrations of folate, vitamin B12, and polyglutamate forms of folate into the more readily ab-
sorbed monoglutamate [21]. Differences in the folatevitamin B6, each of which had a negative correlation
with tHcy. In contrast, patients on PD had higher folate, level between patients on PD versus HD may also be
attributable to differences in dialysis losses [22–24]. Wevitamin B12 and vitamin B6 levels, and a mean tHcy level
significantly lower than the mean value for HD patients. favor the likelihood that the differences between HD
and PD patients in hyperhomocysteinemia and in plasmaAt these higher values of plasma folate and vitamin B12,
the inverse correlation between plasma homocysteine folate levels relate to lower dialytic losses of folate, al-
though we acknowledge that information regarding theand folate levels observed in patients of HD was not
demonstrable in patients on PD. handling of folate in dialysis needs to be updated to
more current membranes and procedures.The most logical explanation for the lower prevalence
of hyperhomocysteinemia in these patients on PD is their The significant correlation between homocysteine and
folate in HD patients indicates that responsiveness tohigher levels of plasma folate. There is ample evidence
that folate is the main determinant of homocysteine lev- folate persisted in these patients even at high circulat-
ing folate levels (Fig. 1). In contrast, for patients on PD,els in ESRD [5, 14, 15] and that folic acid supplementa-
tion decreases homocysteine levels in patients with there was no significant correlation between homocys-
teine and folate (Fig. 1), demonstrating a lack of respon-chronic renal failure with or without dialysis [8, 9, 16–18],
although correction to normal values may not be com- siveness to folate at the high circulating levels seen in
these patients. The mechanisms for this difference inmon [17]. We showed previously that patients on dialysis
appear to be relatively resistant to the action of folate folate responsiveness between these patients are unclear.
Our findings do not exclude a homocysteine-loweringon homocysteine levels [5].
The basis for the higher folate levels in patients on effect of folate in PD patients but are consistent with a
process that is saturated at their higher folate levels.PD is not clear. The differences between folate and vita-
min B12 levels in HD and PD patients are not attributable Janssen et al gave folic acid supplements to patients on
PD in whom folate levels were normal and demonstratedto poorer compliance with vitamin supplements because
adherence was approximately 72% in both groups. Di- that homocysteine concentrations decreased and folate
levels increased [18]. This suggests that the lower dosesetary differences between the two groups were not for-
mally assessed in detail, but there were no readily appar- of folic acid often given as routine supplements are likely
to produce a maximal homocysteine-lowering effect inent differences between the groups in this respect.
Plasma folate and vitamin B12 levels were high in both PD patients.
We noted other differences between HD and PD pa-groups compared with the normal population, indicating
supranormal folate levels in PD patients. tients in the determinants of homocysteine. For example,
in PD, but not HD patients, vitamin B12 correlated sig-There is limited evidence that folate absorption may
be impaired in HD patients by the presence of inhibitors nificantly and independently with homocysteine in a
model that included age, sex, diabetes, hypertension,of folate conjugase inhibitors [19, 20] that cleave dietary
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risk of atherosclerosis in end-stage renal disease and is closely
higher homocysteine and lower folate or vitamin B6 lev- linked to plasma folate and pyridoxine concentrations. Circulation
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